This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ascidian Therapeutics, Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: The Innovations of Robert Bell
Introduction
Robert Bell is an accomplished inventor based in Boston, MA (US). He has made significant contributions to the field of genetic research, particularly in the development of nucleic acid trans-splicing molecules. His work aims to address critical disorders associated with mutations in the ABCA4 gene.
Latest Patents
Robert Bell holds 1 patent for his invention related to ABCA4 trans-splicing molecules. These innovative molecules are designed to correct mutations in the ABCA4 gene, which are linked to disorders such as Stargardt Disease and cone-rod dystrophy. The patent outlines methods for using these nucleic acid trans-splicing molecules to treat conditions associated with ABCA4 mutations, providing a promising avenue for therapeutic interventions.
Career Highlights
Robert Bell is currently associated with Ascidian Therapeutics, Inc., where he continues to advance his research in genetic therapies. His work is pivotal in the development of treatments that could significantly improve the quality of life for individuals affected by genetic disorders.
Collaborations
He collaborates with notable colleagues, including Rebekka Krumbach and Scott J Dooley, who contribute to the innovative research environment at Ascidian Therapeutics.
Conclusion
Robert Bell's contributions to genetic research and his innovative patent for ABCA4 trans-splicing molecules highlight his commitment to advancing medical science. His work has the potential to transform the treatment landscape for genetic disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile